From what I heard in the interview, Rebecca's comment on scarcity of neurosurgeons was about the trials themselves, not the final product.
Given this scarcity, the trials become not only expensive but logistically challenging to plan and conduct.
Her feeling seems to be that CHM's limited resources are better focused on the other trials... at least for now.
- Forums
- ASX - By Stock
- Webinar 17/06/24
From what I heard in the interview, Rebecca's comment on...
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
CHM (ASX) Chart |
Day chart unavailable